Raman Pharma is a UK based MHRA and VMD Licensed Wholesaler supplying to the Human and Veterinary Market. We are a family run company ambitiously changing the face of the Pharmaceutical and Veterinary Market alike in order to serve the needs of our customers and their patients.
Our Philosophy and business are structured around the requirements of our customers and we are committed to giving them our upmost attention and care. We believe in delivering quality and value to our customers wherever they may be.
The Herbal Horse and Pet is a South African manufacturer of a very innovative range of supplements for horses, dogs and cats. Their philosophy of using a large number of different ingredients in small amounts mimics nature in that the healing effect of the ingredients is maximised while undesirable side-effects are minimised. These unique formulations, in conjunction with 21st century scientific research and techniques are what they call “cutting edge nature”.
They are manufactured in a GMP Compliant Factory and has a large following from riders and pet owners across the world. Please follow the link to the website – www.theherbalhorse.co.uk to see all the amazing blogs and the ability to purchase these products online. The Equine and Pet Range were introduced to the UK Market in September 2014 by Raman Pharma to give the UK a taste of the future in equine and companion animal nutritional supplements.
PSNC has published Briefing 043/19: Pharmacy Quality Scheme – Foot and eye screening (retinopathy) checks for patients with diabetes to assist community pharmacy contractors with getting ready to meet the diabetes quality criterion of the Pharmacy Quality Scheme (PQS), which contractors need to start working towards from 1st October 2019. The Briefing explains how to...
A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 13 Issue 1 August 2019) has been published and includes articles on: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping Fingolimod (Gilenya▼): increased risk of congenital malformations; new contraindication...
Following the announcement of a five-year deal for community pharmacy, PSNC has been holding a series of roadshow events for community pharmacists across England. The events are hosted by PSNC Chief Executive Simon Dukes and his team and are being held to help community pharmacy contractors and anyone working in community pharmacies to understand the...
This PSNC Briefing provides community pharmacy contractors with guidance on meeting the diabetes quality criterion for the 2019/20 Pharmacy Quality Scheme (PQS), which is one of five quality criteria that community pharmacy contractors will need to meet to be able to claim for the Prevention domain. PSNC Briefing 043/19: Pharmacy Quality Scheme – Foot and...
Community pharmacy contractors can now access an online recording of our webinar about the new NHS Community Pharmacist Consultation Service (CPCS). Almost 500 people tuned in to yesterday’s webinar, co-hosted by Alastair Buxton, PSNC’s Director of NHS Services, and colleagues from NHS England and NHS Improvement (NHSE&I). During the webinar, the presenters explained how the...
In a follow up from its guidance A Menu of Interventions for Productive Healthy Ageing, published in March 2019, Public Health England (PHE) has distributed* sets of cards which provide information to pharmacy teams on how to support older people to improve the quality of their lives. These cards are designed to guide conversations with...
The General Pharmaceutical Council (GPhC) has begun making pharmacy inspection reports available in the public domain. A new website has been created to enable members of the public to view redacted copies of inspection reports. Visitors will be told whether a pharmacy has met or not met all of the core standards for registered pharmacies, as...
Support is now available from PSNC and on PharmOutcomes to assist community pharmacy contractors with meeting the asthma quality criterion of the 2019/20 Pharmacy Quality Scheme. Contractors are therefore encouraged to review this support and consider implementing a process (many contractors may already have a process in place to identify patients to meet this criterion, as...
This PSNC Briefing provides contractors with guidance for the 2019/20 Pharmacy Quality Scheme (PQS) on meeting the Asthma domain. PSNC Briefing 042/19: Pharmacy Quality Scheme – Asthma referrals If you have any queries on this PSNC Briefing or you require more information, please contact the PSNC Services Team. To browse other PSNC briefings on services and commissioning click...
Teva, the sole manufacturers of Tiagabine (Gabitril) 5mg, 10mg and 15mg tablets, are currently experiencing temporary supply disruptions. Teva, the sole manufacturers of Tiagabine (Gabitril) 5mg, 10mg and 15mg tablets have advised a resupply date of end of October 2019 Supplies are available from specialist importers on an ‘unlicensed’ basis. Ensure that where a prescriber...
Pharmacy, prescription-only (POM), and general sale list (GSL) medicines: apply to move your medicine to a different classification.
MHRA draws a distinction between regulatory function and clinical use of products.
Monthly PDF editions of the Drug Safety Update newsletter from MHRA and its independent advisor the Commission on Human Medicines.
Fingolimod is associated with an increased risk of major congenital malformations including cardiac, renal, and musculoskeletal defects, when used in pregnancy. Women of childbearing potential must use effective contraception during fingolimod treatment and for 2 months after discontinuation.
Cases of pigmentary maculopathy leading to visual impairment have been reported with pentosan polysulfate, particularly after long-term use at high doses. Ensure patients taking pentosan polysulfate have regular ophthalmic examinations and ask them to promptly seek medical advice in case of visual changes.
Prescribers should be alert for neuropsychiatric reactions in patients taking montelukast and carefully consider the benefits and risks of continuing treatment if they occur.
A letter was sent to advise healthcare professionals about a restriction to the indication and route of administration for Mitomycin-C Kyowa 40 mg following the observation of increased sub-visible particles in the drug product on storage. A letter was also sent to notify healthcare professionals of a risk of medication error with various Santen eye drop products during the period of transition to new bottles.
An alert was issued advising against use of Dermapen 3 and Dermapen Cryo Sterile single use needle cartridge tips for Dermapen 3 since their safety cannot be verified.
Guidance for marketing authorisation holders on drafting direct healthcare professional communications (DHPCs) or 'dear Dr letters', including the template.
Medicines that were granted a positive opinion under the early access to medicines scheme (EAMS) which has now expired.
MHRA transactions over £500 made using the government procurement card (GPC).
Information on Medicines and Healthcare products Regulatory Agency spending over £25,000.
Manufactured by CME (a BD company) – function may be affected by fluid getting into the pump and building up over time because of specific cleaning and disinfection practices.
What you need to know about the regulation of medical devices in the UK if we leave the EU with no deal.
We are reviewing our approach to how we engage and involve patients in the work of the Medicines and Healthcare products Regulatory Agency (MHRA).
Marketing authorisations granted in August 2019
Parallel import licenses granted in August 2019
Keep up to date with the latest information from the UK GLP monitoring authority.
The Medicines and Healthcare products Regulatory Agency have released a Strategy for Pharmacopoeial Public Quality Standards for Biological Medicines update.
MHRA and the Bill & Melinda Gates Foundation have begun new research on medicine use which could impact the health of pregnant women around the world.
We are updating the system to simplify and streamline the application process.
Reporting against VMD published standards up to 31 August 2019.
Guidance on applying for an authorisation to manufacture veterinary medicines.
For a marketing authorisation holder only; how to report a defect with a veterinary medicine.
Product defect recall alert for Isathal 10 mg/g eye drops, suspension for dogs, cats and rabbits by Dechra Veterinary Products.
The VMD is experiencing problems receiving and sending emails.
How to legally run a business that deals with the wholesale of animal medicines (veterinary medicinal products) and the WDA Register.
Information for the pharmaceutical industry on new timetables and process improvements for national applications for MAs, ATCs and VHRs.
Web services, such as the Special Imports System and Adverse Event Reporting will be unavailable due to essential electrical maintenance.
Reported problems with the supply of an animal medicine and the date when the issue is expected to be resolved.
You must get permission to export certain drugs and medicines.
As of 9 August 2019 the VMD email addresses will be @vmd.gov.uk.
Details of seizure notice issued to Tudor House Animal Care Ltd, Wolverhampton, West Midlands. Published in August 2019.
Details of the improvement notice issued to Castlehill Veterinary Clinic, Dungannon, County Tyrone. Published in August 2019.
Availability of flunixin solutions for injection.
Report of the ten products for which most Special Import and Special Treatment Certificates (SIC and STC) have been issued by VMD in the UK.
Marketing Authorisations Veterinary Information Service (MAVIS) Hub edition 111.
The Veterinary Products Committee (VPC) is looking to appoint four new members.
This document contains the following information: Veterinary Medicines Directorate annual report and accounts 2018 to 2019.
How to comply with the exemption from the Veterinary Medicines Regulations that allow certain animal medicines to be sold without an authorisation.
Adult smoking rates fell 2.2% from January to July 2019, the equivalent of 200 fewer smokers an hour.
Facebook and Instagram have announced that they will remove posts promoting ‘miracle’ cures and get-slim-quick products.
'Don’t Risk Your Research' aims to raise awareness of the risks incompetence poses to patients, clinical research and organisations.
The designation was based on the Phase II NOBILITY study.
Type II diabetes costs the NHS £8.8 billion a year.
Novartis has also submitted to the EMA for approval in the disease, non-radiographic axial spondyloarthritis.
The recommendation was made based partly on data from the HELP-03 Study, in which Takhzyro reduced the mean number of monthly HAE attacks by 87%.
Research on the topic is vital yet sparse, as data in this area remain limited.
The therapeutics will address key co-morbidities for individuals living with the disease.
The company will not conduct any further trials.
The prestigious and long standing International Clinical Researcher of the Year competition has launched for the 21st year - flying the flag for excellence in global clinical research.
The platform is optimised to work on any device, across multiple regions and languages.
The collaboration will play to Birmingham’s strengths in healthcare data and digitalisation of health care services.
Pharmacists are likely to see people with COPD and asthma more regularly than a GP or nurse, so they play a pivotal role in educating patients on their medicines and inhaler technique.
The treatment proved effectiveness, tolerability and safety in the PERSPECTIVE trial.
Unit 2 Fleet Business Park, Sandy Lane, Church Crookham, Fleet, Hampshire, GU52 8BF
Pharmaceutical and Veterinary Licensed Distributor. WDA (H) 43703 & WDA (V) 43703.
- +44 (0)1252 260 460.
- +44 (0)1276 469 290
Monday to Friday - 09:30 – 18:30
Saturday & Sunday - Closed, Online Ordering Available